drug
AMPHADASE
updated 6mo agoby AMPHASTAR PHARM
community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying AMPHADASE
- phase3A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- phase3A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- phase3Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- EP1Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- phase2Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
- phase3A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
- phase2Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
- phase3A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
News(3)
- Merck barred from making subcutaneous Keytruda in 8 European countriesWith the patent court siding with Halozyme, Merck faces restrictions on a product that won approval in Europe last year.biospace · 19d ago
- Novartis' drug delivery deal with Alteogen; More worker cuts at CellaresPlus, news about Novonesis, Aspen, Fortrea and Northway. Alteogen and Novartis make a deal: The Swiss pharma is licensing Alteogen’s hyaluronidase enzyme, called ALT-B4, which is manufactured using…endpoints · 1mo ago
- Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilarsThe initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.biospace · 2mo ago
Data sources
last refreshed 51m ago
Found something off?
comments(0)
5-min edit window · permanent after that